QNRX
QNRX clinical trials: Quoin Pharmaceuticals Ltd.
Every trial on ClinicalTrials.gov where Quoin Pharmaceuticals Ltd. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 4
- Trials linked
- 4
- As lead sponsor
- 0
- As collaborator
- 3
- Primary completions as lead sponsor, next 90 days
QNRX on the catalyst calendar · QNRX registry changes
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Jan 31, 2027Sponsor estimate | NCT07538583Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton SyndromeQuoin Pharmaceuticals · Netherton Syndrome | QNRXLead | Phase 2/Phase 3 | Recruiting | Locked | Locked | Locked |
| Dec 30, 2026Sponsor estimate | NCT06953466Clinical Study of QRX003 Lotion in Subjects With Netherton SyndromeQuoin Pharmaceuticals · Netherton Syndrome | QNRXLead | Phase 2/Phase 3 | Recruiting | Locked | Locked | Locked |
| Dec 30, 2026Sponsor estimate | NCT05789056Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton SyndromeQuoin Pharmaceuticals · Netherton Syndrome | QNRXLead | Phase 2/Phase 3 | Recruiting | Locked | Locked | Locked |
| Dec 30, 2025Actual | NCT05521438Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton SyndromeQuoin Pharmaceuticals · Netherton Syndrome | QNRXLead | Phase 2/Phase 3 | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Jan 31, 2027Sponsor estimatePhase 2/Phase 3NCT07538583Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton SyndromeQuoin Pharmaceuticals · Netherton SyndromeRecruitingQNRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2026Sponsor estimatePhase 2/Phase 3NCT06953466Clinical Study of QRX003 Lotion in Subjects With Netherton SyndromeQuoin Pharmaceuticals · Netherton SyndromeRecruitingQNRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2026Sponsor estimatePhase 2/Phase 3NCT05789056Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton SyndromeQuoin Pharmaceuticals · Netherton SyndromeRecruitingQNRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2025ActualPhase 2/Phase 3NCT05521438Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton SyndromeQuoin Pharmaceuticals · Netherton SyndromeActive, not recruitingQNRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 4 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner